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Abstract
Background—Hispanic women have a higher incidence of cervical cancer than all other races 
and ethnicities. In Hispanic subgroups, Mexican American women were among the least likely to 
have received cervical cancer screening. In a recent RCT, Ayudando a las Mujeres con 
Información, Guia, y Amor para su Salud (AMIGAS) was shown to increase cervical cancer 
screening rates among women of Mexican descent at 6 months in all intervention arms compared 
to the control arm. Limited information exists about the economics of interventions to increase 
cervical cancer screening rates among women of Mexican descent.
Purpose—This study aims to estimate the cost-effectiveness of the alternative AMIGAS 
intervention methods for increasing cervical cancer screening among low-income women of 
Mexican descent in three U.S. communities.
Methods—Cost data were collected from 2008 to 2011 alongside the AMIGAS study of 613 
women. Receipt of Pap test within 6 months of intervention was the primary outcome measure in 
the cost-effectiveness analysis, conducted during 2012–2013.
Results—The cost per additional woman screened comparing the video-only intervention to 
usual care was $980. The cost increased to $1,309 with participant time cost included. With an 
additional cost per participant of $3.90 compared to flipchart only, the full AMIGAS program 
(video plus flipchart) yielded 6.8% additional women screened.
Conclusions—Results on the average and incremental cost-effectiveness of the AMIGAS 
program elements may assist health policymakers and program managers to select and 
appropriately budget for interventions shown to increase cervical cancer screening among low-
income women of Mexican descent.
Address correspondence to: David R. Lairson, PhD, University of Texas Health Science Center at Houston School of Public Health, 
1200 Herman Pressler, Houston TX 77030. david.r.lairson@uth.tmc.edu. 
No financial disclosures were reported by the authors of this paper.
HHS Public Access
Author manuscript
Am J Prev Med. Author manuscript; available in PMC 2015 October 13.
Published in final edited form as:














Women without a routine source of health care,1 of low education,2 and low income levels3 
have higher rates of cervical cancer mortality. For average-risk women, the U.S. Preventive 
Services Task Force recommends regular Pap tests beginning at age 21 years and screening 
at least every 3 years (when using the Pap test alone).4,5
In 2009, more than 12,000 women in the U.S. were diagnosed with cervical cancer, with 
Hispanic women having a higher incidence of cervical cancer than all other races and 
ethnicities.6 In Hispanic subgroups, Mexican American women were among the least likely 
to have received cervical cancer screening.7 Hispanic women and women living along the 
U.S.–Mexico border were more likely to die from this disease than others.8
Using effective interventions to address this inequality is a priority.9 The Healthy People 
2020 objective for cervical cancer screening is to increase the percentage of women aged 
21–65 years who have been screened to 93%.9 The Affordable Care Act requires Medicare 
and most private insurance plans to cover certain recommended preventive services, 
including cervical cancer screening, with no cost sharing. The law will increase access to 
health insurance for millions of Americans who have not had a usual source of care and 
regular access to preventive services.10,11
Implementing effective interventions to educate and increase use of preventive services is 
necessary to achieve local and national cancer control and prevention goals.8,9 The 
Community Preventive Services Task Force found strong evidence to support the 
effectiveness of one-on-one education and small media strategies12 for increasing cervical 
cancer screening,13 and recommends these approaches.14
A recent report described the development15 and effectiveness of the Ayudando a las 
Mujeres con Información, Guia, y Amor para su Salud (AMIGAS) intervention in increasing 
Pap test screening among Mexican American women living in the U.S.16 This paper reports 
results of the cost-effectiveness analysis conducted as part of the AMI-GAS study to assess 
the incremental gain in cervical cancer screening compliance compared to the incremental 
cost of moving from a usual care control group to successively more involved interventions 
(i.e., video or flipchart, or video and flipchart delivered by a trained health worker).
Studies have provided evidence on the cost-effectiveness of screening and treatment for 
cervical cancer by screening interval and risk group.17–22 Mandelblatt et al.18 found that 
maximum savings in life could be achieved by screening every 2 years beginning at age 20 
years until death with a combination of Pap and human papilloma-virus (HPV) testing. 
Ending Pap tests at age 75 or 65 years could result in savings while retaining 98%–87% of 
the benefits of lifetime biennial Pap screening.19
Although some studies have also examined the extent to which new screening technologies 
are cost-effective relative to traditional methods,23,24 few examined the cost-effectiveness of 
intervention strategies to increase cervical cancer screening, especially among Hispanic 
women. A cost-effectiveness study of promotion strategies to increase screening for cervical 
cancer at the Kaiser Northwest HMO found an initial letter with follow-up phone call was 
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more cost-effective than strategies using identical initial and follow-up mechanisms (i.e., 
initial letter with letter follow-up or initial phone call with phone follow-up).25
Hispanic women were not specifically targeted in the Kaiser study. A study of the relative 
cost-effectiveness of individual versus group lay educator interventions for Hispanic women 
in Phoenix found little difference in the effect of the interventions and lower cost in the 
group-level program.26 Additional reports about the cost-effectiveness of these interventions 
will provide researchers, program managers, and policy makers with information to 
compare, select, and budget for cervical cancer screening interventions.
This paper presents the cost-effectiveness evaluation of the AMIGAS intervention from the 
payer and payer plus participant perspectives. Although the direct costs may be the main 
budgetary concern for decision makers, the burden on participants in terms of cost and time 
is also important to assess as a major component of the full societal cost and a potential 
factor in the rate of participation in the interventions.
Methods
The cost-effectiveness analysis was conducted alongside the community-based RCT of the 
AMIGAS intervention. The primary intent of the study was to measure the effectiveness of 
key small media components of AMIGAS when used individually or together versus 
control. The research protocol for this study was approved by the University of Texas Health 
Science Center-Houston Committee for the Protection of Human Subjects and the Fred 
Hutchinson Cancer Research Center IRB.
The AMIGAS intervention was designed using Intervention Mapping27 and delivered in 
participants–homes or preferred locations by trained lay health workers (promotoras) in 
either English or Spanish from 2008 through 2011. Promotoras are from the community 
being served and have some training (usually a series of courses) but are not professional 
health workers.
They typically have similar demographic and cultural characteristics as the people they 
serve and act as trusted models and health educators. In Texas, many lay health workers are 
–certified–by the state health department by taking approved classes and continuing 
education. They are paid substantially less than health educators with a BS or MS degree or 
nurses.
Promotoras received detailed instructions to guide their use of educational materials in 
describing cervical cancer, related risk factors, benefits of screening, and the screening 
process. The AMIGAS intervention includes a video that portrays women from the 
community addressing common barriers and beliefs about cervical cancer screening, a 
flipchart with additional information for reinforcing the video, and handouts that can be used 
at the discretion of the promotora to further reinforce the messages.
The trial was conducted in El Paso and Houston TX and the Yakima Valley WA. Women of 
Mexican descent aged ≥21 years with no history of cancer, no hysterectomy, and no cervical 
cancer screening within the past 3 years were eligible. Further details about the recruitment 
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process and demographic characteristics of the women in each intervention site are 
presented elsewhere.16
Following a baseline interview, 613 eligible women were randomly assigned to one of three 
intervention arms or a control arm (Figure 1). Study arms differed by the types of materials 
the promotoras used to deliver the program, flipchart, a video, or both the flipchart and 
video. These versions of AMIGAS were compared to a control group. Women in the control 
group may have received cervical cancer screening education in clinics but did not receive 
promotora-led education.
The follow-up interview occurred at least 6 months after the intervention to assess whether 
participants received a Pap test since the initial contact. Regardless of how the participants 
answered (yes or no), receipt or non-receipt of Pap test was confirmed with the identified 
clinic.15,16
Cost-Effectiveness Analysis
The economic analysis was conducted during 2012–2013 to provide information on the cost-
effectiveness of the AMIGAS interventions. The economic evaluation includes data and an 
analytic framework for decision making from both the participant and provider perspectives.
Participants are persons in the trial who are the targets of the screening promotion 
interventions. Providers are clinics or health agencies that are responsible for paying for the 
screening-promotion interventions. The analysis assumes that providers are responsible for 
all resource costs of the intervention but not participant time cost. Intent to treat–based point 
estimates of cost and screening outcome were applied for the comparison of groups. This 
conservative strategy analyzes results for all randomized participants.
If outcome data were missing, screening was assumed to not have occurred. Considerable 
evidence supports the effectiveness and cost-effectiveness of cervical cancer screening.5 
Therefore, the task was to estimate the cost-effectiveness of this evidence-based intervention 
designed to increase cervical cancer screening, not to provide evidence of the cost-
effectiveness of screening tests.
The primary measure of cost-effectiveness was the incremental cost effectiveness ratio 
(ICER). ICERs were obtained by dividing the additional per target individual cost by the 
additional percentage of target individuals who were screened by the end of the follow-up 
period, comparing the control group to the video group, the flipchart group, and the video 
plus flipchart group, moving from the least costly to the most costly intervention. For 
example, equation (1) represents the ICER calculation comparing the video arm to the 
control arm:
(1)
where the overbar represents mean cost in the study arm and % represents the percentage of 
persons screened in the study arm.
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The primary outcome (one-time Pap test at the 6-month follow-up) was measured among 
participants who previously had not adhered to recommended screening guidelines. Receipt 
of Pap test was evaluated under four scenarios: (1) those receiving the full AMIGAS 
intervention, which includes both the flipchart and video; (2) those receiving the AMIGAS 
with the flipchart only (no video); (3) those receiving the AMIGAS with the video only (no 
flipchart); and (4) those in the control group (Figure 1).
Costs
Micro-costing (tracking resource use and weighting by their prices) was selected over gross 
costing (tracking final services and weighting by their prices). Although micro-costing was 
labor intensive, it was the most precise form of cost determination and recommended by the 
U.S. Panel on Cost-Effectiveness Analysis.28
Costs included were those for planning, training staff, recruiting eligible women to receive 
the intervention, and delivering the intervention. Resource unit prices were obtained from 
project administrative records, and participant time was valued by the median full-time 
weekly earnings for Hispanic women.29 Promo-tora visit time and travel distance were 
tracked via encounter and travel reimbursement logs. Participant time was tracked via 
promotora encounter forms. Travel cost was estimated with the Internal Revenue Service 
estimate of cost per mile traveled.30
Overhead was estimated at 35% of direct cost, following previous standards used in 
community health prevention studies.31 The overhead estimate covers office space, utilities, 
housekeeping, basic office equipment, and administration by a manager who is responsible 
for the overall community health program. Project records were used to itemize, quantify, 
and value multimedia equipment and supplies. Cost estimates were in 2008 U.S. dollars.
Sensitivity Analysis
Estimates and methods uncertainty were evaluated with sensitivity analysis to determine 
effects of alternative parameter estimates and methods on the ICERs. Key parameters for 
sensitivity analysis included the overhead cost rate and size of the target population with a 
range of 300 to 5,000, assuming fixed costs for training staff, planning meetings, 
coordinator, and materials over that range. Costs and effect were not discounted owing to 
the short duration of the program.
Because the ICER is a ratio statistic with the potential for a zero denominator, the variance 
formula necessary to compute CIs becomes more difficult. Alternatively, the nonparametric 
bootstrap resampling method (1,000 re-samples) was used to obtain 95% confidence limits 
for the ICERs.32 SAS/STAT, version 9.2 (SAS Institute Inc., Cary NC), was used to conduct 
the bootstrap analysis.
Results
The intention-to-treat results for 613 participants in the AMIGAS RCT were utilized for the 
cost-effectiveness analysis. Participants were aged 21–66 years with an median age of 38 
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years, 87.6% were born in Mexico, lived 16 years in the U.S. on average, 68.6% were 
married, 93.0% were ever pregnant, 89.0% ever had a pap test, and 18.1% reported some 
healthcare coverage.16 The three intervention arms yielded significantly higher screening 
rates compared to the 24.8% screening rate achieved in the control arm.
The screening rate for participants in the full AMIGAS arm (52.3%) was 6.8% higher than 
for the flipchart-only arm and 11.0% higher than for the video-only arm, although the 
differences between the interventions did not reach statistical significance at the 0.05 
level.16 Results from this study demonstrated that the per person cost of full, flipchart-only, 
and video-only interventions were $223, $219, and $216, respectively, from the payer plus 
participant perspective; and $165, $165, and $162 respectively, from the payer perspective 
(Table 1).
From the payer plus participant perspective, this distribution of cost was similar across the 
three arms: cost for the payer plus participant perspective included participant time (25%); 
recruitment (23%); conducting the intervention (21%); local travel (16%); and staff training 
(8%). From the payer perspective, about 17% of the cost was for recruitment, 16% for 
conducting the intervention, 21% for local travel, and 10% for training.
Table 2 shows the cost per additional person screened or the ICER from the payer plus 
participant perspective was $1,308 (95% CI=$869, $2,396) comparing no intervention to the 
video intervention; $76 (95% CI=–$7, $7) comparing the video to flip-chart arm; and $57 
(95% CI=–$13, $6) comparing the flipchart to the full intervention arm. The declining 
ICERs as interventions become more costlyimply that screening of additional women can be 
achieved with minimal additional cost compared to the next less costly intervention.
For example, given that it costs only $3.90 more per person to deliver the full intervention 
arm compared to the flipchart-only arm and 6.8% more participants get screened, the cost 
per additional woman screened is only $57. Each of the 1,000 bootstrap samples yielded a 
cost-effectiveness ratio with effect and cost being higher in the intervention groups 
compared to the control group. In no sample was the cost of the video intervention higher 
and effect lower than the control group.
The ICER computed from the payer perspective only, excluding participant cost, was $980 
(95% CI=$650, $1,974) comparing controls to the video-only intervention; $71 (95% CI=–
$4.10, $6.60) comparing the video-only to flipchart-only arm; and $4 (95% CI=–$1.80, 
$1.60) comparing the flipchart-only to the full intervention arm (Table 2).
The ICER declined at a decreasing rate when expanding the intervention to a larger 
population with the same level of fixed costs (planning, staff training, project coordinator, 
and others) incurred in the trial when the target population was hypothetically increased 
from 600 to 1,250; the estimated payer cost per additional woman screened using the video 
declined from $908 to $811 and to $685 when the target population was 5,000 women (data 
not shown).
Alternative assumptions for the overhead rate had minimal effect on the ICERs. For 
example, increasing the overhead rate from 30% to 40% increased the incremental cost per 
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additional woman receiving a Pap test by approximately 6% when comparing the video-only 
arm to the controls in both payer perspective and the societal perspective analyses.
Discussion
The AMIGAS intervention produced a statistically significant increase in cervical cancer 
screening rates among low-income women of Mexican descent in diverse urban and rural 
settings who had never or rarely been screened. The cost per additional women screened 
comparing the video-only version of the program to controls was approximately $980. The 
cost increased to $1,309 when participant time was included in the cost estimates.
If these costs are considered feasible and of value, program decision makers may consider 
employing the full AMIGAS intervention. With a minimal additional cost of $3.90 per 
participant compared to the flipchart-only arm, the full AMIGAS intervention yields 6.8% 
additional women screened.
The study results clearly demonstrate, however, that the video- and the flipchart-only 
conditions are also successful in increasing cervical cancer screening among women of 
Mexican descent.16 Likewise, our analysis demonstrated that the small media components of 
the AMIGAS intervention are cost-effective methods of increasing cervical cancer screening 
in this population.
These cost findings should be considered an upper bound in replicating AMIGAS in non-
research settings. The program was delivered in the participant–s home, resulting in 
substantial travel cost. Depending upon the context, home visits may present safety 
challenges. AMIGAS training includes guidance about promotoras–safety, including 
delivery in pairs, which increases cost. As providers gain additional experience and become 
more efficient in delivering AMIGAS, the program effect may be enhanced and costs may 
be lowered.
Given that the cost of recruitment for prevention programs ranges from 20% to 40% of the 
cost of implementation,33 decision makers may consider leveraging AMIGAS to incorporate 
additional cancer prevention services. This strategy may reduce the cost per prevention 
behavior outcome by a factor dependent on the number of targeted behaviors and additional 
costs incurred because of greater complexity of the intervention.
Chirikos et al.34 described an economic analysis of a multi-prevention service intervention 
whereby implementing a central clinic reminder system targeting compliance with screening 
for breast, cervical, and colorectal cancer reduced the marginal cost of achieving compliance 
with an additional test. They apportioned the cost of the intervention over the sample, 
depending on the distribution of tests (one, two, or three) indicated for the patients in the 
sample.
Programs with a similar level of fixed inputs that serve more people may reduce average 
cost when replicating AMIGAS by spreading the fixed costs incurred for initial planning, 
staff training, and project coordination. As in most studies, the trial was sized to measure the 
effect and not for maximum efficiency. The planning and training costs can be spread over 
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more participants, although the maximum number that could be recruited and served without 
expanding the fixed inputs is unknown.
The reader is therefore cautioned that the simulation is intended to provide an indication of 
how the ICER may decline with increased target population. Alternatively, attention should 
be given to the level of difficulty in reaching additional women, which may require 
additional coordinators and associated training costs, thereby reducing the efficiency gains 
of serving a larger group.
The most relevant comparison of the findings to the cost-effectiveness literature is with the 
Phoenix study of cancer screening interventions for underserved Latinas.26 This study found 
that interventions to increase screening for breast, cervical, and colorectal cancers averaged 
$103 in 2006 U.S. dollars when delivered to groups and $392 when delivered to individuals, 
both from the perspective of the sponsoring organization.
Larkey and colleagues26 estimated an average cost of $516 per screening for the group 
strategy and $1,716 per screening for the individual strategy, under the conservative 
assumption of intention-to-treat. The efficiency of the group strategy was further supported 
by considering the imputed ICER. The incremental cost per additional screening was $4,736 
when moving from the group to the individual strategy.26 These findings compare favorably 
to a cost per additional screening of $980 in this study, when comparing the control group to 
the video-only strategy, clearly indicating a more efficient one-on-one intervention.
Although AMIGAS was designed for one-on-one and group formats, further research is 
needed to determine the effectiveness of the group format. Nevertheless, the use of 
evidence-based interventions such as AMIGAS with groups may improve the odds of 
having an effective intervention when applied in settings that were not included in the 
original study.
Two additional studies provide comparison for estimates of cost effectiveness. A study of 
phone- and letter-based interventions to increase cervical cancer screening at the Kaiser 
Permanente Northwest health plan found a cost per additional screening that ranged from 
$185 (letter with phone follow-up) to $1,117 (letter with letter follow-up) in 1996 U.S. 
dollars.25 This equals about $254 and $1,533 in 2008 prices.35 Each intervention was 
compared to a no intervention, zero cost control group.
A direct mail versus outreach intervention study to increase cervical cancer screening among 
Chinese American women in Seattle and Vancouver found a cost per additional screening 
that ranged from $415 (outreach) to $676 (direct mail) in 1999 U.S. dollars. This equals 
about $536 and $874 in 2008 prices. Each comparison was based on intent-to-treat and 
compared to a no intervention, zero cost control group.36
Limitations to the cost-effectiveness analysis include self-report of personnel time and 
screening outcome, and the application of an assumed overhead cost rate. Consistency of 
personnel time estimates across study sites (data not shown) suggest that relative costs were 
not distorted by measurement error. Medical chart reviews showed that the validity of self-
reported screening outcome in this study was comparable or better than that found in other 
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studies where self-report of Pap test screening was validated by clinical record review.16 
The overhead is based on previously reported standard rates and is applied equally to each 
study arm, minimizing the effect of measurement error on the relative cost of the 
interventions.
Strengths of the study include the concurrent conduct of the economic evaluation with a 
community-based RCT, inclusion of the payer and payer plus participant perspectives, and 
direct micro-costing of the planning and operating costs of the intervention.37 Inclusion of 
three geographically dispersed sites further enhances the generalizability of the findings for 
the intended population of low-income women of Mexican descent.
In summary, a screening test for cervical cancer saves lives and is cost-effective,18 but low-
income women of Mexican descent are disproportionately underscreened.1,7,8 The 
effectiveness and cost-effectiveness of the AMIGAS intervention suggest value in 
developing evidence-based interventions with and for populations that are traditionally 
medically underserved. This study adds important economic evaluation information to the 
limited body of evidence on evidence-based cervical cancer screening, which may assist 
health policy makers and program managers select among and budget for programs to 
enhance screening for cervical cancer and achieve lower mortality rates among low-income 
women of Mexican descent.
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Table 1
Average cost by study arm, $
Cost category Full (video + flipchart; n=134) Video (n=144) Flipchart (n=146)
Payer and participant
 Staff time for recruitment 28.20 28.20 28.20
 Participant time for recruitment 21.30 21.30 21.30
 Staff time for intervention 28.30 24.80 24.90
 Participant time for intervention 21.60 18.80 19.00
 Staff time for travel 17.70 18.90 20.60
 Mileage for travel 15.50 15.80 16.80
 Training for staff 16.90 16.90 16.90
 Meetings for staff 7.90 7.90 7.90
 Coordinator time 8.90 8.90 8.90
 Material for interventions 7.50 7.50 7.50
 Average direct cost 173.80 168.90 172.0
 Overheada 49.20 47.00 47.10
 Total average cost 223.00 215.90 219.10
Payer
 Average direct cost 130.90 128.80 131.70
 Overheadb 34.20 32.90 33.00
 Total average cost 165.00 161.70 164.70
a
35% of direct cost, excluding travel
b
35% of direct cost, excluding participant cost and travel
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